Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00432575
Status:
COMPLETED
Last Update Posted:
2009-04-15
First Post:
2007-02-07
Brief Title:
Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation SURSMOKE
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel Group Fixed-Dose 8-Week Treatment Multi-Center Trial Evaluating the Efficacy and the Safety of 3 Oral Doses of Surinabant as an Aid to Smoking Cessation in Cigarette Smokers
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Surinabant is a new potent and selective antagonist for the cannabinoid CB1 receptor which might be clinically useful in the treatment of dependence to nicotine
The primary study objective is the assessment of efficacy of 3 doses of surinabant on abstinence from smoking in cigarette smokers The main secondary objectives are the effect of surinabant on body weight and its clinical and biological safety
The primary study objective is the assessment of efficacy of 3 doses of surinabant on abstinence from smoking in cigarette smokers The main secondary objectives are the effect of surinabant on body weight and its clinical and biological safety
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT 2006-005334-2L | None | None | None |